Belite Bio Q2 FY26 net loss widens to $28.41 million - BLTE News | RalliesBelite Bio Q2 FY26 net loss widens to $28.41 million
B
BLTE• Tinlarebant NDA accepted by FDA
- FDA accepted the tinlarebant NDA for STGD1 with Priority Review.
- The PDUFA target action date is set for Feb. 12, 2027.
Quarterly loss widens as spending increases
- Belite Bio posted a Q2 net loss of USD 28.4 million, widening from a USD 16.3 million loss a year earlier.
- R&D expense climbed 64.9% to USD 18.2 million, driven mainly by a royalty payment tied to a license milestone.
- SG&A costs more than doubled to USD 16.7 million on higher professional fees and wages from team expansion.
- Other income rose to USD 6.6 million from USD 1.3 million, helped by interest on deposits and U.S. Treasury bills and notes.
TBCH
•
